Cancer Vaccine News

Moderna's mRNA melanoma vaccine, intismeran, has shown promise in early trials by slowing the recurrence of skin cancer in patients. This development suggests t

New research suggests that vaccinating against cancer is becoming possible, with the latest results showing promise, though they are not yet definitive.

A personalized cancer vaccine developed by Moderna and Merck has shown success in a final-stage melanoma trial. Researchers are hopeful this approach could be u

Moderna stock dropped 12% after a 177% surge, as investors evaluate the company's intismeran cancer vaccine success, future demand, pricing, and other cancer tr

Moderna's stock surged by 120% following positive Phase 3 trial results for its mRNA cancer vaccine when combined with Merck's Keytruda, offering new hope for m